Price Band
₹461 - ₹485
Lot Size
1200
Issue Size
₹1378 Cr
GMP
N/A
Subscription
109.35x
Analyzing...
IPO Schedule
1
Open
24 Jun 2025
2
Close
26 Jun 2025
3
Allotment
14 Oct 2025
4
Listing
16 Oct 2025
About Rubicon Research Ltd
Rubicon Research Ltd is a contract research and manufacturing services (CRAMS) provider specializing in complex and innovative pharmaceutical formulations. They focus on providing solutions for bioavailability enhancement, modified release, and dosage form development.
Key Strengths
- Strong track record of innovation and complex formulation development.
- Established relationships with leading pharmaceutical companies.
- High return on equity (ROE) of 35.23% indicates efficient capital utilization.
- Attractive P/E ratio of 11.72 suggests potential undervaluation compared to industry peers.
- Focus on niche segments within the pharmaceutical industry provides a competitive advantage.
Risk Factors
- •Dependence on key clients could impact revenue if relationships are disrupted.
- •Intense competition in the CRAMS industry may put pressure on pricing and margins.
- •Regulatory changes in the pharmaceutical industry could affect product development and commercialization.
Valuation Analysis
The IPO appears reasonably priced given the company's high ROE and relatively low P/E ratio, suggesting potential for appreciation; however, investors should carefully consider the inherent risks associated with the CRAMS industry.
IPO Details
ExchangeBSE
SegmentMAINBOARD
ISININE0Y0E01012
NSE SymbolRUBICON
Face Value₹10
Lot Size1200
Issue Size₹1378 Cr
Key Metrics
ROE35.23%
ROCE37.09%
P/E Ratio11.72
Industry P/E20
EPS7.76
PAT Margin7.70%
Debt/Equity0.35
Growth & Quality
ProfitableYes ✓
Subscription
Total0.54x
Imbalance Ratio34.0x
Documents
Registrar
LINK
Key Dates
Open Date24 Jun 2025
Close Date26 Jun 2025
Allotment14 Oct 2025
Listing16 Oct 2025